Venture Capital Company Catalia Capital Management announced today The closure of its more than $ 400 million fund IV, as first reported by Bloomberg. The fund will continue the company’s thesis on supporting health and biotechnology companies.
The company was founded in 2020 and made more than 100 investments, according to Pitchbook. The IV Fund of Catalia has mainly supported 16 companies, including the Diagnostic Company PinkDX and the Drug Discovery Company Superluminal Medications.
The company previously raised $ 381 million fund III in 2020 and $ 100 million fund II in 2019, with a pitch book.
The biotechnical market was especially not resistant to last year’s corporate decline, followed by higher interest rates and a cooler IPO market. The market total earned only $ 12 billion last year, a sharp decline from its peak of $ 152.3 billion in 2023, as Bloomberg reported.
